Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Titel:
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment
Auteur:
Nowicka, Malgorzata Hilton, Laura K. Ashton-Key, Margaret Hargreaves, Chantal E. Lee, Chern Foxall, Russell Carter, Matthew J. Beers, Stephen A. Potter, Kathleen N. Bolen, Christopher R. Klein, Christian Knapp, Andrea Mir, Farheen Rose-Zerilli, Matthew Burton, Cathy Klapper, Wolfram Scott, David W. Sehn, Laurie H. Vitolo, Umberto Martelli, Maurizio Trneny, Marek Rushton, Christopher K. Slack, Graham W. Farinha, Pedro Strefford, Jonathan C. Oestergaard, Mikkel Z. Morin, Ryan D. Cragg, Mark S.